Journal
TRENDS IN MICROBIOLOGY
Volume 23, Issue 10, Pages 653-665Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.tim.2015.07.005
Keywords
-
Categories
Funding
- Ligue Nationale contra Is Cancer
- Fondation ARC, Sidaction
- Fondation pour la Recherche Medicate
- French National Research Agency (ANR)
- Investissements d'Avenir' program [ANR-10-LABX-53-01]
Ask authors/readers for more resources
Monoclonal antibodies (mAbs) are increasingly being considered as agents to fight severe viral diseases. So far, they have essentially been selected and used on the basis of their virus-neutralizing activity and/or cell-killing activity to blunt viral propagation via direct mechanisms. There is, however, accumulating evidence that they can also induce long-lasting protective antiviral immunity by recruiting the endogenous immune system of infected individuals during the period of immunotherapy. Exploiting this property may revolutionize antiviral mAb-based immunotherapies, with benefits for both patients and healthcare systems.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available